NO931536L - Fremgangsmaater og sammensetninger for undertrykkelse av allograftforkastelse hos pattedyr - Google Patents
Fremgangsmaater og sammensetninger for undertrykkelse av allograftforkastelse hos pattedyrInfo
- Publication number
- NO931536L NO931536L NO93931536A NO931536A NO931536L NO 931536 L NO931536 L NO 931536L NO 93931536 A NO93931536 A NO 93931536A NO 931536 A NO931536 A NO 931536A NO 931536 L NO931536 L NO 931536L
- Authority
- NO
- Norway
- Prior art keywords
- allograft
- rejection
- mammals
- allographic
- suppression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60782690A | 1990-10-31 | 1990-10-31 | |
PCT/US1991/008143 WO1992007581A1 (en) | 1990-10-31 | 1991-10-31 | Methods and compositions for suppressing allograft rejection in mammals |
Publications (2)
Publication Number | Publication Date |
---|---|
NO931536D0 NO931536D0 (no) | 1993-04-27 |
NO931536L true NO931536L (no) | 1993-04-27 |
Family
ID=24433875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO93931536A NO931536L (no) | 1990-10-31 | 1993-04-27 | Fremgangsmaater og sammensetninger for undertrykkelse av allograftforkastelse hos pattedyr |
Country Status (11)
Country | Link |
---|---|
US (2) | US5681556A (ja) |
EP (1) | EP0555413A4 (ja) |
JP (1) | JP2547162B2 (ja) |
KR (1) | KR0161235B1 (ja) |
AU (1) | AU662500B2 (ja) |
BR (1) | BR9107055A (ja) |
CA (1) | CA2093513C (ja) |
HU (1) | HUT63957A (ja) |
IL (1) | IL99864A (ja) |
NO (1) | NO931536L (ja) |
WO (1) | WO1992007581A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5641474A (en) * | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
US5645820A (en) * | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
DK0503648T3 (da) * | 1991-03-12 | 2000-10-30 | Biogen Inc | CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3 |
MX9203138A (es) * | 1991-03-12 | 1992-09-01 | Biogen Inc | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
GB9319429D0 (en) * | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
WO1995020661A1 (en) * | 1994-01-27 | 1995-08-03 | Bresatec Ltd. | Materials and methods for management of hyperacute rejection in human xenotransplantation |
US5849991A (en) | 1994-01-27 | 1998-12-15 | Bresatch Limited | Mice homozygous for an inactivated α 1,3-galactosyl transferase gene |
JPH08239324A (ja) * | 1995-03-03 | 1996-09-17 | Fusanori Hamashima | 免疫抑制剤 |
US20020155117A1 (en) * | 1996-04-04 | 2002-10-24 | Nicole Suciu-Foca | Method for detecting organ allograft rejection and uses thereof |
EP2301567A1 (en) * | 1997-02-28 | 2011-03-30 | Enzo Therapeutics, Inc. | Selective immune down regulation (SIDR) for transplantation |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
US6685936B2 (en) * | 1999-10-12 | 2004-02-03 | Osiris Therapeutics, Inc. | Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation |
US20020012667A1 (en) * | 2000-05-16 | 2002-01-31 | Mcmichael John | Method for preventing allograft rejection |
ATE367823T1 (de) | 2000-05-24 | 2007-08-15 | Us Health | E-selectin zur behandlung oder vorbeugung von schlaganfall |
US20030170258A1 (en) * | 2001-05-09 | 2003-09-11 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (SIDR) |
US7858095B2 (en) | 2001-07-24 | 2010-12-28 | Astellas Us Llc | Method for treating or preventing sclerotic disorders using CD-2 binding agents |
KR20050039700A (ko) * | 2001-10-25 | 2005-04-29 | 아테로제닉스, 인코포레이티드 | 이식거부 치료용 화합물 및 치료 방법 |
WO2005115436A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5899419A (ja) * | 1981-12-07 | 1983-06-13 | Green Cross Corp:The | 免疫抑制剤 |
JPS59116224A (ja) * | 1982-10-01 | 1984-07-05 | デイミトリ・アダモポ−ロス | 免疫反応を抑制する組成物およびその製法 |
US4635627A (en) * | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
US5130297A (en) * | 1988-06-23 | 1992-07-14 | Anergen, Inc. | Conjugates useful in ameliorating autoimmunity MHC-II-peptide |
US5011037A (en) * | 1989-11-30 | 1991-04-30 | Adolph Coors Company | Container end member |
RU2054180C1 (ru) * | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
-
1991
- 1991-10-27 IL IL9986491A patent/IL99864A/xx not_active IP Right Cessation
- 1991-10-31 KR KR1019930701248A patent/KR0161235B1/ko not_active IP Right Cessation
- 1991-10-31 AU AU89426/91A patent/AU662500B2/en not_active Ceased
- 1991-10-31 BR BR919107055A patent/BR9107055A/pt not_active Application Discontinuation
- 1991-10-31 WO PCT/US1991/008143 patent/WO1992007581A1/en not_active Application Discontinuation
- 1991-10-31 EP EP9292902860A patent/EP0555413A4/en not_active Withdrawn
- 1991-10-31 HU HU931252A patent/HUT63957A/hu unknown
- 1991-10-31 JP JP4500909A patent/JP2547162B2/ja not_active Expired - Lifetime
- 1991-10-31 CA CA002093513A patent/CA2093513C/en not_active Expired - Fee Related
-
1993
- 1993-04-27 NO NO93931536A patent/NO931536L/no not_active Application Discontinuation
- 1993-11-29 US US08/159,044 patent/US5681556A/en not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/461,661 patent/US5788968A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5788968A (en) | 1998-08-04 |
CA2093513A1 (en) | 1992-05-01 |
AU662500B2 (en) | 1995-09-07 |
US5681556A (en) | 1997-10-28 |
HU9301252D0 (en) | 1993-07-28 |
KR0161235B1 (ko) | 1998-12-01 |
CA2093513C (en) | 1999-03-23 |
BR9107055A (pt) | 1993-09-21 |
WO1992007581A1 (en) | 1992-05-14 |
JP2547162B2 (ja) | 1996-10-23 |
IL99864A (en) | 2000-11-21 |
NO931536D0 (no) | 1993-04-27 |
AU8942691A (en) | 1992-05-26 |
JPH05508663A (ja) | 1993-12-02 |
KR930701969A (ko) | 1993-09-08 |
IL99864A0 (en) | 1992-08-18 |
HUT63957A (en) | 1993-11-29 |
EP0555413A1 (en) | 1993-08-18 |
EP0555413A4 (en) | 1994-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO931536L (no) | Fremgangsmaater og sammensetninger for undertrykkelse av allograftforkastelse hos pattedyr | |
Wachsmuth et al. | Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression | |
Smith et al. | The adoptive transfer of pregnancy-induced unresponsiveness to male skin grafts with thymus-dependent cells. | |
AR059693A2 (es) | Una composicion farmaceutica de micofenolato y su uso | |
TAWFIK et al. | Implication of prostaglandin E2 in soluble factor‐mediated immune suppression by murine decidual cells | |
WO2017179840A1 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물 | |
NO965207L (no) | Sammensetning for indusering av mukosal immunrespons | |
BR9611802A (pt) | Composições farmacêuticas | |
NO20002605D0 (no) | Speroider, fremstillingsmetode og farmasøytiske sammensetninger | |
BR0110779A (pt) | Composições e métodos para adquirir supressão imunológica | |
HUT71310A (en) | Methods and preparations for suppression of proliferative response and induction of tolerance wita polymorphic class ii mhc allopeptides | |
Yazici et al. | A new rat model of maxilla allotransplantation | |
DE68917738D1 (de) | Therapeutisch aktive substituierte Benzimidazole und Verfahren zu ihrer Herstellung. | |
TNSN00145A1 (fr) | Derives de streptogramines, leur preparation et les compositions qui les contiennent | |
Kukita et al. | Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells | |
Ercan et al. | The effects of cold-restraint stress on urinary bladder wall compared with interstitial cystitis morphology | |
ES2118087T3 (es) | Composiciones inmunosupresoras. | |
LV10267A (lv) | Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai | |
Kawahara et al. | Prolongation of heterotopic cardiac allografts in rats by cyclosporin A | |
Serrano-Lopez et al. | Fibroblasts at the curtain call: from ensemble to principal dancers in immunometabolism and inflammaging | |
Campbell et al. | T-cell control of IgA production. I. Distribution, activation conditions and culture of isotype-specific regulatory helper cells. | |
CO4230094A1 (es) | Composiciones | |
Andres et al. | Structural observations on epithelioid and giant cells in experimental autoimmune tubulointerstitial nephritis in guinea pigs. | |
ES2126923T3 (es) | 8-fluoro-antraciclinas, procedimientos para su preparacion y composiciones farmaceuticas que las contienen. | |
DK630088D0 (da) | Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |